Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Zhornitsky

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Pharmaceuticals (Basel, Switzerland)|November 28, 2013
Cannabidiol in humans-the quest for therapeutic targetsSimon Zhornitsky, Stéphane Potvin
Schizophrenia Research and Treatment|September 12, 2012
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic ReviewSimon Zhornitsky, Emmanuel Stip
The American Journal on Addictions|March 11, 2025
Drug overdose and suicidal intentionality among young adults in methadone treatmentYifrah Kaminer, Simon Zhornitsky
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 18, 2015
Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysisStéphane Potvin, Simon Zhornitsky, Emmanuel Stip
Behavioural Brain Research|October 6, 2010
Evidence that the reward attenuating effect of the D1-like antagonist, SCH-23390, is not mediated by its agonist action at the 5-HT2c receptorsFaïza Benaliouad, Simon Zhornitsky, Pierre-Paul Rompré
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 18, 2010
Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategiesEmmanuel Stip, Simon Zhornitsky, Stéphane Potvin, et al.
The Australian and New Zealand Journal of Psychiatry|March 2, 2011
Relationship between insight into cognition, extrapyramidal symptoms and mental illness in schizophreniaSimon Zhornitsky, Stéphane Potvin, Ginette Aubin, et al.
Drug Safety|September 13, 2012
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysisHoda Moteshafi, Simon Zhornitsky, Sarah Brunelle, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 8, 2010
Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamineSimon Zhornitsky, Stéphane Potvin, Emmanuel Stip, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 7, 2021
Noradrenergic correlates of chronic cocaine craving: neuromelanin and functional brain imagingWuyi Wang, Simon Zhornitsky, Sheng Zhang, et al.
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Pharmaceuticals (Basel, Switzerland)|November 28, 2013
Cannabidiol in humans-the quest for therapeutic targetsSimon Zhornitsky, Stéphane Potvin
Schizophrenia Research and Treatment|September 12, 2012
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic ReviewSimon Zhornitsky, Emmanuel Stip
The American Journal on Addictions|March 11, 2025
Drug overdose and suicidal intentionality among young adults in methadone treatmentYifrah Kaminer, Simon Zhornitsky
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 18, 2015
Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysisStéphane Potvin, Simon Zhornitsky, Emmanuel Stip
Behavioural Brain Research|October 6, 2010
Evidence that the reward attenuating effect of the D1-like antagonist, SCH-23390, is not mediated by its agonist action at the 5-HT2c receptorsFaïza Benaliouad, Simon Zhornitsky, Pierre-Paul Rompré
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 18, 2010
Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategiesEmmanuel Stip, Simon Zhornitsky, Stéphane Potvin, et al.
The Australian and New Zealand Journal of Psychiatry|March 2, 2011
Relationship between insight into cognition, extrapyramidal symptoms and mental illness in schizophreniaSimon Zhornitsky, Stéphane Potvin, Ginette Aubin, et al.
Drug Safety|September 13, 2012
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysisHoda Moteshafi, Simon Zhornitsky, Sarah Brunelle, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 8, 2010
Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamineSimon Zhornitsky, Stéphane Potvin, Emmanuel Stip, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 7, 2021
Noradrenergic correlates of chronic cocaine craving: neuromelanin and functional brain imagingWuyi Wang, Simon Zhornitsky, Sheng Zhang, et al.
Pageof 9